Please enable JavaScript to continue using this application.

Compare $COAG vs $STOK | Chartloom

Compare

$COAG vs $STOK

Hemab Therapeutics Holdings Inc · Stoke Therapeutics Inc

COAG

Hemab Therapeutics Holdings Inc

STOK

Stoke Therapeutics Inc

Compare $COAG vs $STOK

Comparing Hemab Therapeutics Holdings Inc and Stoke Therapeutics Inc

COAGHemab Therapeutics Holdings Inc

STOKStoke Therapeutics Inc

COAGHemab Therapeutics Holdings Inc

Market cap

$1.48B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-7.0%

52W performance

-7.0%

FCF yield

0.0%

STOKStoke Therapeutics Inc

Market cap

$1.54B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

47.27x

Rev growth (TTM)

-86.2%

YTD performance

-19.9%

52W performance

-18.9%

FCF yield

-11.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

COAG

STOK

Detailed metrics comparison

COAG

Hemab Therapeutics Holdings Inc

STOK

Stoke Therapeutics Inc

Market Cap

COAG$1.48B

STOK$1.54B

Enterprise Value

COAG$1.24B

STOK$1.43B

Price

COAG$31.62

STOK$24.74

P/E Ratio

COAGN/A

STOKN/A

P/S Ratio

COAG0.00x

STOK55.85x

EV/Sales

COAG0.00x

STOK51.86x

EV/EBITDA

COAG0.00x

STOK53.69x

P/B Ratio

COAG3.20x

STOK4.78x

P/FCF Ratio

COAGN/A

STOKN/A

EV/FCF

COAG0.00x

STOK-7.92x

PEG Ratio

COAGN/A

STOKN/A

Forward P/E (NTM)

COAGN/A

STOKN/A

Forward P/S (NTM)

COAGN/A

STOK47.27x

Revenue (TTM)

COAG$0

STOK$28M

Revenue Growth (YoY)

COAGN/A

STOK-86.2%

Forward Rev Growth

COAG1014.0%

STOK62.9%

Gross Margin (TTM)

COAG0.0%

STOK0.0%

Operating Margin (TTM)

COAG0.0%

STOK0.0%

EBITDA Margin (TTM)

COAG0.0%

STOK-803.4%

Net Margin (TTM)

COAG0.0%

STOK-753.6%

FCF Margin (TTM)

COAGN/A

STOK-654.9%

Net Income (TTM)

COAG$-47M

STOK$-208M

FCF (TTM)

COAG$0

STOK$-181M

EPS (TTM)

COAG-$1.00

STOK-$3.15

ROE (TTM)

COAG0.0%

STOK-5936.0%

ROA (TTM)

COAG0.0%

STOK-5146.0%

ROIC (TTM)

COAG0.0%

STOK-5936.0%

Cash

COAG$237M

STOK$110M

Debt

COAG$0

STOK$0

Net Cash/Debt

COAG$237M

STOK$110M

Current Ratio (TTM)

COAG35.85x

STOK7.69x

Quick Ratio (TTM)

COAG35.48x

STOK7.34x

Debt/Equity (TTM)

COAG0.00x

STOK0.00x

Debt/Assets (TTM)

COAG0.0%

STOK0.0%

Interest Coverage (TTM)

COAGN/A

STOKN/A

Net Debt/EBITDA (TTM)

COAG0.00x

STOK0.00x

Beta

COAG-0.87

STOK1.36

52W Performance

COAG-7.0%

STOK-18.9%

YTD Performance

COAG-7.0%

STOK-19.9%

% from 52W High

COAG-42.9%

STOK-38.5%

% from 52W Low

COAG37.5%

STOK21.8%

Asset Turnover (TTM)

COAG0.00x

STOK0.07x

FCF Yield (TTM)

COAG0.0%

STOK-11.7%

Earnings Yield (TTM)

COAG-3.2%

STOK-13.5%

Dividend Yield (TTM)

COAGN/A

STOKN/A

Rule of 40

COAG0.0

STOK-741.1

EV/GP/RG

COAGN/A

STOKN/A

Ticker research

View COAG research View STOK research

Metric	COAG Hemab Therapeutics Holdings Inc	STOK Stoke Therapeutics Inc
Market & Valuation
Market Cap	$1.48B	$1.54B
Enterprise Value	$1.24B	$1.43B
Price	$31.62	$24.74
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	55.85x
EV/Sales	0.00x	51.86x
EV/EBITDA	0.00x	53.69x
P/B Ratio	3.20x	4.78x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-7.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	47.27x
Revenue & Growth
Revenue (TTM)	$0	$28M
Revenue Growth (YoY)	N/A	-86.2%
Forward Rev Growth	1014.0%	62.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-803.4%
Net Margin (TTM)	0.0%	-753.6%
FCF Margin (TTM)	N/A	-654.9%
Net Income (TTM)	$-47M	$-208M
FCF (TTM)	$0	$-181M
EPS (TTM)	-$1.00	-$3.15
ROE (TTM)	0.0%	-5936.0%
ROA (TTM)	0.0%	-5146.0%
ROIC (TTM)	0.0%	-5936.0%
Financial Health
Cash	$237M	$110M
Debt	$0	$0
Net Cash/Debt	$237M	$110M
Current Ratio (TTM)	35.85x	7.69x
Quick Ratio (TTM)	35.48x	7.34x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.87	1.36
52W Performance	-7.0%	-18.9%
YTD Performance	-7.0%	-19.9%
% from 52W High	-42.9%	-38.5%
% from 52W Low	37.5%	21.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	0.0%	-11.7%
Earnings Yield (TTM)	-3.2%	-13.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-741.1
EV/GP/RG	N/A	N/A
Ticker research	View COAG research	View STOK research

Valuation

P/S Ratio

COAG

0.00x

STOK

55.85x

EV/FCF

STOK

-7.92x

COAG

0.00x

Growth & revenue

Revenue Growth TTM

STOK

-86.2%

Forward Revenue Growth

COAG

1014.0%

STOK

62.9%

Profitability & performance

Gross Margin

COAG

0.0%

STOK

0.0%

ROE

COAG

0.0%

STOK

-5936.0%

FCF Yield %

COAG

0.0%

STOK

-11.7%

52-Week Performance

COAG

-7.0%

STOK

-18.9%

Detailed metrics comparison

COAG

Hemab Therapeutics Holdings Inc

STOK

Stoke Therapeutics Inc

Market Cap

COAG$1.48B

STOK$1.54B

Enterprise Value

COAG$1.24B

STOK$1.43B

Price

COAG$31.62

STOK$24.74

P/E Ratio

COAGN/A

STOKN/A

P/S Ratio

COAG0.00x

STOK55.85x

EV/Sales

COAG0.00x

STOK51.86x

EV/EBITDA

COAG0.00x

STOK53.69x

P/B Ratio

COAG3.20x

STOK4.78x

P/FCF Ratio

COAGN/A

STOKN/A

EV/FCF

COAG0.00x

STOK-7.92x

PEG Ratio

COAGN/A

STOKN/A

Forward P/E (NTM)

COAGN/A

STOKN/A

Forward P/S (NTM)

COAGN/A

STOK47.27x

Revenue (TTM)

COAG$0

STOK$28M

Revenue Growth (YoY)

COAGN/A

STOK-86.2%

Forward Rev Growth

COAG1014.0%

STOK62.9%

Gross Margin (TTM)

COAG0.0%

STOK0.0%

Operating Margin (TTM)

COAG0.0%

STOK0.0%

EBITDA Margin (TTM)

COAG0.0%

STOK-803.4%

Net Margin (TTM)

COAG0.0%

STOK-753.6%

FCF Margin (TTM)

COAGN/A

STOK-654.9%

Net Income (TTM)

COAG$-47M

STOK$-208M

FCF (TTM)

COAG$0

STOK$-181M

EPS (TTM)

COAG-$1.00

STOK-$3.15

ROE (TTM)

COAG0.0%

STOK-5936.0%

ROA (TTM)

COAG0.0%

STOK-5146.0%

ROIC (TTM)

COAG0.0%

STOK-5936.0%

Cash

COAG$237M

STOK$110M

Debt

COAG$0

STOK$0

Net Cash/Debt

COAG$237M

STOK$110M

Current Ratio (TTM)

COAG35.85x

STOK7.69x

Quick Ratio (TTM)

COAG35.48x

STOK7.34x

Debt/Equity (TTM)

COAG0.00x

STOK0.00x

Debt/Assets (TTM)

COAG0.0%

STOK0.0%

Interest Coverage (TTM)

COAGN/A

STOKN/A

Net Debt/EBITDA (TTM)

COAG0.00x

STOK0.00x

Beta

COAG-0.87

STOK1.36

52W Performance

COAG-7.0%

STOK-18.9%

YTD Performance

COAG-7.0%

STOK-19.9%

% from 52W High

COAG-42.9%

STOK-38.5%

% from 52W Low

COAG37.5%

STOK21.8%

Asset Turnover (TTM)

COAG0.00x

STOK0.07x

FCF Yield (TTM)

COAG0.0%

STOK-11.7%

Earnings Yield (TTM)

COAG-3.2%

STOK-13.5%

Dividend Yield (TTM)

COAGN/A

STOKN/A

Rule of 40

COAG0.0

STOK-741.1

EV/GP/RG

COAGN/A

STOKN/A

Ticker research

View COAG research View STOK research

Metric	COAG Hemab Therapeutics Holdings Inc	STOK Stoke Therapeutics Inc
Market & Valuation
Market Cap	$1.48B	$1.54B
Enterprise Value	$1.24B	$1.43B
Price	$31.62	$24.74
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	55.85x
EV/Sales	0.00x	51.86x
EV/EBITDA	0.00x	53.69x
P/B Ratio	3.20x	4.78x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-7.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	47.27x
Revenue & Growth
Revenue (TTM)	$0	$28M
Revenue Growth (YoY)	N/A	-86.2%
Forward Rev Growth	1014.0%	62.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-803.4%
Net Margin (TTM)	0.0%	-753.6%
FCF Margin (TTM)	N/A	-654.9%
Net Income (TTM)	$-47M	$-208M
FCF (TTM)	$0	$-181M
EPS (TTM)	-$1.00	-$3.15
ROE (TTM)	0.0%	-5936.0%
ROA (TTM)	0.0%	-5146.0%
ROIC (TTM)	0.0%	-5936.0%
Financial Health
Cash	$237M	$110M
Debt	$0	$0
Net Cash/Debt	$237M	$110M
Current Ratio (TTM)	35.85x	7.69x
Quick Ratio (TTM)	35.48x	7.34x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.87	1.36
52W Performance	-7.0%	-18.9%
YTD Performance	-7.0%	-19.9%
% from 52W High	-42.9%	-38.5%
% from 52W Low	37.5%	21.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	0.0%	-11.7%
Earnings Yield (TTM)	-3.2%	-13.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-741.1
EV/GP/RG	N/A	N/A
Ticker research	View COAG research	View STOK research